Biomarker-Guided Treatment Selection in RA | Q2 2026
This educational material is in development by independent expert faculty. Support for this activity is being sought through unrestricted educational grants. If supported, supporters will have no role in faculty selection, content development, conclusions, or dissemination.
Status: In development; support not yet awarded.
Prioritized open questions in biomarker-guided treatment selection in RA and, for each, the type of evidence that would materially reduce uncertainty (e.g., prospective validation, reproducibility, workflow impact).
Areas of disagreement or uncertainty are explicitly preserved and labeled. Non-consensus is a valid outcome. This material does not provide treatment recommendations.
Content forthcoming
Expected ~60-90 days post-session